Arkolith/Insider Trading/RPRX/Form 4

Urist Marshall

EVP, Research & InvestmentsRoyalty Pharma plc (RPRX) · full profile →Form 4 · filed Dec 3, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$1.7M
Net Open-Market Flow
-$1.7M
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 1, 2025Sell(S)18K$39.90$728K26K
Dec 1, 2025Sell(S)23K$39.93$932K183K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001838139-25-000006) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML